NCT06451757 - KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

November 28, 2025

Primary Completion Date

January 2, 2028

Study Completion Date

January 2, 2028

Conditions

Mitochondrial DiseasesMaternally Inherited Diabetes and Deafness (MIDD)Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation

Interventions

DRUG

Sonlicromanol

Oral administration of 100 mg sonlicromanol (KH176) twice daily during 52 weeks

DRUG

Placebo

Oral administration of 100 mg placebo twice daily during 52 weeks